Antoni Miralles

Prof. Antoni Miralles

Laboratory of Neurophysiology, Biology Department, University of Balearic Islands (UIB)
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
MRMargarita R. Ramis
Margarita R. Ramis
SESusana Esteban
Susana Esteban
AMAntoni Miralles
Antoni Miralles
DTDunxian Tan
Dunxian Tan
Russel ReiterRussel Reiter
Russel Reiter

30 January 2018 in Current Neuropharmacology
Verified
Journal Article
Open access
FSFiorella Sarubbo
Fiorella Sarubbo
SESusana Esteban
Susana Esteban
AMAntoni Miralles
Antoni Miralles
DMDavid Moranta
David Moranta
Classically the oxidative stress and more recently inflammatory processes have been identified as the major causes of brain aging. Oxidative stress and inflammation affect each other, but there is more information about the effects of oxidative stress on aging than regarding the contribution of inflammation on it. In the intense research for methods to delay or mitigate the effects of aging, are interesting polyphenols, natural molecules synthesized by plants (e.g. resveratrol). Their antioxidant and anti-inflammatory properties become them useful molecules in the prevention of aging. The antiaging effects of polyphenols could be due to several related mechanisms, among which are the prevention of oxidative stress, SIRT1 activation and inflammaging modulation, via regulation of some signaling pathways, such as NF-κB. In this review, we describe the positive effects of polyphenols on the prevention of the changes that occur during aging in the brain and their consequences on cognition, emphasizing the possible modulation of inflammaging by polyphenols through a SIRT1-mediated mechanism.

13 August 2015 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MRM. R. Ramis
M. R. Ramis
SESusana Esteban
Susana Esteban
AMAntoni Miralles
Antoni Miralles
DTDun-Xian Tan
Dun-Xian Tan
RRR. J. Reiter
R. J. Reiter
Oxidative damage is related to aging and a wide range of human disorders. Mitochondria are in large part responsible for free radical production and they are also main targets of the attack of these toxic molecules. The resulting deleterious effects of the damage to mitochondria can be prevented by antioxidants. Melatonin is an endogenouslyproduced indoleamine that modulates numerous functions, including mitochondria-related functions; this result from its capacity to penetrate all morphophysiological barriers and to enter all subcellular compartments due to its amphiphilic nature. Furthermore, this indoleamine and its metabolites are powerful antioxidants and scavengers of free radicals, protecting cellular membranes, the electron transport chain and mitochondrial DNA from oxidative damage. These properties may make melatonin a potent protector against a variety of free radical-related diseases. By comparison, other conventional antioxidants have less efficacy due to their limited access to the mitochondria. In recent years, research has focused on the advancement of mitochondria-targeted antioxidants, such as MitoQ (composed by the lipophilic triphenylphosphonium cation conjugated to the endogenous antioxidant coenzyme Q10) and MitoE (composed by the triphenylphosphonium cation attached to the antioxidant α-tocopherol). Mitochondria-targeted antioxidants accumulate in several hundred-fold greater concentrations within mitochondria and protect these critical organelles from oxidative damage. Melatonin also seems to be a mitochondria-targeted antioxidant and has similar protective actions as the synthetic antioxidants. Further work is required to determine the therapeutic properties of these antioxidants in ameliorating diseases related to mitochondrial dysfunction.

14 October 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Pablo V EscribáPablo V Escribá
Pablo V Escribá
Andres OzaitaAndres Ozaita
Andres Ozaita
CRCatalina Ribas
Catalina Ribas
AMAntoni Miralles
Antoni Miralles
EFElfrieda Fodor
Elfrieda Fodor
JGJesús A. García-Sevilla
Jesús A. García-Sevilla
Heterotrimeric G proteins (peripheral proteins) conduct signals from membrane receptors (integral proteins) to regulatory proteins localized to various cellular compartments. They are in excess over any G protein-coupled receptor type on the cell membrane, which is necessary for signal amplification. These facts account for the large number of G protein molecules bound to membrane lipids. Thus, the protein-lipid interactions are crucial for their cellular localization, and consequently for signal transduction. In this work, the binding of G protein subunits to model membranes (liposomes), formed with defined membrane lipids, has been studied. It is shown that although G protein α-subunits were able to bind to lipid bilayers, the presence of nonlamellar-prone phospholipids (phosphatidylethanolamines) enhanced their binding to model membranes. This mechanism also appears to be used by other (structurally and functionally unrelated) peripheral proteins, such as protein kinase C and the insect protein apolipophorin III, indicating that it could constitute a general mode of protein-lipid interactions, relevant in the activity and translocation of some peripheral (amphitropic) proteins from soluble to particulate compartments. Other factors, such as the presence of cholesterol or the vesicle surface charge, also modulated the binding of the G protein subunits to lipid bilayers. Conversely, the binding of G protein-coupled receptor kinase 2 and the G protein β-subunit to liposomes was not increased by hexagonally prone lipids. Their distinct interactions with membrane lipids may, in part, explain the different cellular localizations of all of these proteins during the signaling process.

14 August 2017 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
FSFiorella Sarubbo
Fiorella Sarubbo
MRM. R. Ramis
M. R. Ramis
CKC. Kienzer
C. Kienzer
SAS. Aparicio
S. Aparicio
SESusana Esteban
Susana Esteban
DMDavid Moranta
David Moranta

1 August 2005 in European Journal of Pharmacology
Verified
Journal Article
Closed access
AMAntoni Miralles
Antoni Miralles
SESusana Esteban
Susana Esteban
ASAntonio Sastre-Coll
Antonio Sastre-Coll
DMDavid Moranta
David Moranta
VAVíctor José Asensio
Víctor José Asensio
JGJesús Andrés García-Sevilla
Jesús Andrés García-Sevilla